

SUMMARY OF THE COMBINATION

(Under Regulation 13 (1B) of the The Competition Commission of India (Procedure in regard to the transaction of business relating to combinations) Regulations, 2011)

1. The Transaction concerns the acquisition of E.I. Du Pont De Nemours and Company's ("**Du Pont**") pharmaceutical grade 134a/P fluorochemical propellants business by SRF Limited ("**SRF**") (together, the "**Parties**"). In this regard, the Parties had executed a Commercial Assets Sale and IP License Agreement along with certain ancillary documents.
2. SRF is engaged in the manufacture of chemical based industrial intermediates. Its business portfolio in India covers technical textiles, fluorochemicals, specialty chemicals, packaging films and engineering plastics. Over the years, SRF has expanded its footprint beyond national boundaries and is currently also active in Thailand and South Africa.
3. Du Pont is a global business house primarily focused on three strategic priority areas: Agriculture & Nutrition, Advanced Materials, and Bio-Based Industrials. In India, Du Pont markets a wide range of products in varied market segments including agriculture, food and nutrition, health care, home and construction, electronics, safety and protection, transportation and infrastructure.¹
4. The relevant market to which the Transaction relates would be the global market for pharmaceutical grade HFC 134a.

¹http://www2.dupont.com/India_Country_Site/en_IN/assets/downloads/DuPont%20India%20at%20a%20Glance.pdf